Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.

Mov Disord. 2019 May;34(5):708-716. doi: 10.1002/mds.27565. Epub 2018 Dec 21.

PMID:
30575996
2.

Drug repurposing from the perspective of pharmaceutical companies.

Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, Papapetropoulos S, Grossman I, Laifenfeld D.

Br J Pharmacol. 2018 Jan;175(2):168-180. doi: 10.1111/bph.13798. Epub 2017 May 18. Review.

3.

Inhibition of the mitochondrial pyruvate carrier protects from excitotoxic neuronal death.

Divakaruni AS, Wallace M, Buren C, Martyniuk K, Andreyev AY, Li E, Fields JA, Cordes T, Reynolds IJ, Bloodgood BL, Raymond LA, Metallo CM, Murphy AN.

J Cell Biol. 2017 Apr 3;216(4):1091-1105. doi: 10.1083/jcb.201612067. Epub 2017 Mar 2.

4.

The targeted eosinophil-lowering effects of dexpramipexole in clinical studies.

Dworetzky SI, Hebrank GT, Archibald DG, Reynolds IJ, Farwell W, Bozik ME.

Blood Cells Mol Dis. 2017 Mar;63:62-65. doi: 10.1016/j.bcmd.2017.01.008. Epub 2017 Jan 16.

PMID:
28178599
5.

Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.

Kalinichev M, Le Poul E, Boléa C, Girard F, Campo B, Fonsi M, Royer-Urios I, Browne SE, Uslaner JM, Davis MJ, Raber J, Duvoisin R, Bate ST, Reynolds IJ, Poli S, Celanire S.

J Pharmacol Exp Ther. 2014 Sep;350(3):495-505. doi: 10.1124/jpet.114.214437. Epub 2014 Jun 19.

6.

Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.

Smith KM, Browne SE, Jayaraman S, Bleickardt CJ, Hodge LM, Lis E, Yao L, Rittle SL, Innocent N, Mullins DE, Boykow G, Reynolds IJ, Hill D, Parker EM, Hodgson RA.

Eur J Pharmacol. 2014 Apr 5;728:31-8. doi: 10.1016/j.ejphar.2014.01.052. Epub 2014 Jan 31.

PMID:
24486705
7.

A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease.

Le Poul E, Boléa C, Girard F, Poli S, Charvin D, Campo B, Bortoli J, Bessif A, Luo B, Koser AJ, Hodge LM, Smith KM, DiLella AG, Liverton N, Hess F, Browne SE, Reynolds IJ.

J Pharmacol Exp Ther. 2012 Oct;343(1):167-77. doi: 10.1124/jpet.112.196063. Epub 2012 Jul 11.

PMID:
22787118
8.

Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity.

Nikonova EV, Xiong Y, Tanis KQ, Dawson VL, Vogel RL, Finney EM, Stone DJ, Reynolds IJ, Kern JT, Dawson TM.

Hum Mol Genet. 2012 Jan 1;21(1):163-74. doi: 10.1093/hmg/ddr451. Epub 2011 Oct 4.

9.

Attenuation of scratch-induced reactive astrogliosis by novel EphA4 kinase inhibitors.

Parmentier-Batteur S, Finger EN, Krishnan R, Rajapakse HA, Sanders JM, Kandpal G, Zhu H, Moore KP, Regan CP, Sharma S, Hess JF, Williams TM, Reynolds IJ, Vacca JP, Mark RJ, Nantermet PG.

J Neurochem. 2011 Sep;118(6):1016-31. doi: 10.1111/j.1471-4159.2011.07375.x. Epub 2011 Aug 16.

10.

High throughput monitoring of amyloid-β(42) assembly into soluble oligomers achieved by sensitive conformation state-dependent immunoassays.

Zhao WQ, Toolan D, Hepler RW, Wolfe AL, Yu Y, Price E, Uebele VN, Schachter JB, Reynolds IJ, Renger JJ, McCampbell A, Ray WJ.

J Alzheimers Dis. 2011;25(4):655-69. doi: 10.3233/JAD-2011-102022.

PMID:
21483096
11.

Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease.

Chen HK, Ji ZS, Dodson SE, Miranda RD, Rosenblum CI, Reynolds IJ, Freedman SB, Weisgraber KH, Huang Y, Mahley RW.

J Biol Chem. 2011 Feb 18;286(7):5215-21. doi: 10.1074/jbc.M110.151084. Epub 2010 Nov 30.

12.

PISA, a novel pharmacodynamic assay for assessing poly(ADP-ribose) polymerase (PARP) activity in situ.

Lubbers LS, Rowe BA, Hodge LM, Browne SE, Gundersdorf R, Jones P, Hess FJ, Reynolds IJ.

J Pharmacol Toxicol Methods. 2010 May-Jun;61(3):319-28. doi: 10.1016/j.vascn.2010.01.012. Epub 2010 Feb 2.

PMID:
20132901
13.

Mitochondrial trafficking and morphology in neuronal injury.

Rintoul GL, Reynolds IJ.

Biochim Biophys Acta. 2010 Jan;1802(1):143-50. doi: 10.1016/j.bbadis.2009.09.005. Epub 2009 Sep 10. Review.

14.

Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.

Yang ZQ, Barrow JC, Shipe WD, Schlegel KA, Shu Y, Yang FV, Lindsley CW, Rittle KE, Bock MG, Hartman GD, Uebele VN, Nuss CE, Fox SV, Kraus RL, Doran SM, Connolly TM, Tang C, Ballard JE, Kuo Y, Adarayan ED, Prueksaritanont T, Zrada MM, Marino MJ, Graufelds VK, DiLella AG, Reynolds IJ, Vargas HM, Bunting PB, Woltmann RF, Magee MM, Koblan KS, Renger JJ.

J Med Chem. 2008 Oct 23;51(20):6471-7. doi: 10.1021/jm800830n. Epub 2008 Sep 26.

PMID:
18817368
15.

Glutamate mobilizes [Zn2+] through Ca2+ -dependent reactive oxygen species accumulation.

Dineley KE, Devinney MJ 2nd, Zeak JA, Rintoul GL, Reynolds IJ.

J Neurochem. 2008 Sep;106(5):2184-93. doi: 10.1111/j.1471-4159.2008.05536.x. Epub 2008 Jul 4.

16.

Measurement of cation movement in primary cultures using fluorescent dyes.

Reynolds IJ.

Curr Protoc Neurosci. 2001 May;Chapter 7:Unit7.11. doi: 10.1002/0471142301.ns0711s04.

PMID:
18428522
17.

Thermal nociception and TRPV1 function are attenuated in mice lacking the nucleotide receptor P2Y2.

Malin SA, Davis BM, Koerber HR, Reynolds IJ, Albers KM, Molliver DC.

Pain. 2008 Sep 15;138(3):484-96. doi: 10.1016/j.pain.2008.01.026. Epub 2008 Mar 14.

18.

Nuclear and mitochondrial interaction involving mt-Nd2 leads to increased mitochondrial reactive oxygen species production.

Gusdon AM, Votyakova TV, Reynolds IJ, Mathews CE.

J Biol Chem. 2007 Feb 23;282(8):5171-9. Epub 2006 Dec 21.

19.

Mitochondrial trafficking and morphology in healthy and injured neurons.

Chang DT, Reynolds IJ.

Prog Neurobiol. 2006 Dec;80(5):241-68. Epub 2006 Dec 26. Review.

PMID:
17188795
20.

Mitochondrial trafficking to synapses in cultured primary cortical neurons.

Chang DT, Honick AS, Reynolds IJ.

J Neurosci. 2006 Jun 28;26(26):7035-45.

21.

Differences in mitochondrial movement and morphology in young and mature primary cortical neurons in culture.

Chang DTW, Reynolds IJ.

Neuroscience. 2006 Aug 25;141(2):727-736. doi: 10.1016/j.neuroscience.2006.01.034. Epub 2006 Jun 23.

PMID:
16797853
22.

Nitric oxide inhibits mitochondrial movement in forebrain neurons associated with disruption of mitochondrial membrane potential.

Rintoul GL, Bennett VJ, Papaconstandinou NA, Reynolds IJ.

J Neurochem. 2006 May;97(3):800-6. Epub 2006 Mar 29.

23.

Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.

Chang DT, Rintoul GL, Pandipati S, Reynolds IJ.

Neurobiol Dis. 2006 May;22(2):388-400. Epub 2006 Feb 9.

PMID:
16473015
24.

Zn2+ inhibits mitochondrial movement in neurons by phosphatidylinositol 3-kinase activation.

Malaiyandi LM, Honick AS, Rintoul GL, Wang QJ, Reynolds IJ.

J Neurosci. 2005 Oct 12;25(41):9507-14.

25.

Distinct characteristics of Ca(2+)-induced depolarization of isolated brain and liver mitochondria.

Vergun O, Reynolds IJ.

Biochim Biophys Acta. 2005 Sep 5;1709(2):127-37.

26.

Zinc causes loss of membrane potential and elevates reactive oxygen species in rat brain mitochondria.

Dineley KE, Richards LL, Votyakova TV, Reynolds IJ.

Mitochondrion. 2005 Feb;5(1):55-65.

PMID:
16060292
27.

Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures.

Kress GJ, Reynolds IJ.

Neurobiol Dis. 2005 Dec;20(3):639-45. Epub 2005 Jun 29.

PMID:
15996475
28.

Direct visualization of mitochondrial zinc accumulation reveals uniporter-dependent and -independent transport mechanisms.

Malaiyandi LM, Vergun O, Dineley KE, Reynolds IJ.

J Neurochem. 2005 Jun;93(5):1242-50.

30.

Synaptosomal dopamine uptake in rat striatum following controlled cortical impact.

Wilson MS, Chen X, Ma X, Ren D, Wagner AK, Reynolds IJ, Dixon CE.

J Neurosci Res. 2005 Apr 1;80(1):85-91.

PMID:
15704194
31.

Simultaneous detection of intracellular free calcium and zinc using fura-2FF and FluoZin-3.

Devinney MJ 2nd, Reynolds IJ, Dineley KE.

Cell Calcium. 2005 Mar;37(3):225-32.

PMID:
15670869
32.

Detection of hydrogen peroxide with Amplex Red: interference by NADH and reduced glutathione auto-oxidation.

Votyakova TV, Reynolds IJ.

Arch Biochem Biophys. 2004 Nov 1;431(1):138-44.

PMID:
15464736
33.

Mitochondrial stop and go: signals that regulate organelle movement.

Reynolds IJ, Rintoul GL.

Sci STKE. 2004 Sep 21;2004(251):PE46. Review.

PMID:
15383673
34.

Mitochondrial trafficking in neurons: a key variable in neurodegeneration?

Reynolds IJ, Malaiyandi LM, Coash M, Rintoul GL.

J Bioenerg Biomembr. 2004 Aug;36(4):283-6. Review.

PMID:
15377858
35.
36.

Fluorescence detection of redox-sensitive metals in neuronal culture: focus on iron and zinc.

Reynolds IJ.

Ann N Y Acad Sci. 2004 Mar;1012:27-36. Review.

PMID:
15105253
37.

PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS.

Venneti S, Lopresti BJ, Wang G, Bissel SJ, Mathis CA, Meltzer CC, Boada F, Capuano S 3rd, Kress GJ, Davis DK, Ruszkiewicz J, Reynolds IJ, Murphey-Corb M, Trichel AM, Wisniewski SR, Wiley CA.

J Clin Invest. 2004 Apr;113(7):981-9.

38.

Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation.

Glading A, Bodnar RJ, Reynolds IJ, Shiraha H, Satish L, Potter DA, Blair HC, Wells A.

Mol Cell Biol. 2004 Mar;24(6):2499-512.

39.
40.

Ectopic expression of the catalytic subunit of telomerase protects against brain injury resulting from ischemia and NMDA-induced neurotoxicity.

Kang HJ, Choi YS, Hong SB, Kim KW, Woo RS, Won SJ, Kim EJ, Jeon HK, Jo SY, Kim TK, Bachoo R, Reynolds IJ, Gwag BJ, Lee HW.

J Neurosci. 2004 Feb 11;24(6):1280-7.

41.

Spontaneous changes in mitochondrial membrane potential in single isolated brain mitochondria.

Vergun O, Votyakova TV, Reynolds IJ.

Biophys J. 2003 Nov;85(5):3358-66.

42.
43.

Glutamate decreases mitochondrial size and movement in primary forebrain neurons.

Rintoul GL, Filiano AJ, Brocard JB, Kress GJ, Reynolds IJ.

J Neurosci. 2003 Aug 27;23(21):7881-8.

44.

New perspectives on mitochondrial morphology in cell function.

Brocard JB, Rintoul GL, Reynolds IJ.

Biol Cell. 2003 Jul;95(5):239-42. Review.

PMID:
12941521
45.

Zinc inhibition of cellular energy production: implications for mitochondria and neurodegeneration.

Dineley KE, Votyakova TV, Reynolds IJ.

J Neurochem. 2003 May;85(3):563-70. Review.

46.

Elevated intracellular zinc and altered proton homeostasis in forebrain neurons.

Dineley KE, Brocard JB, Reynolds IJ.

Neuroscience. 2002;114(2):439-49.

PMID:
12204213
47.

A reevaluation of neuronal zinc measurements: artifacts associated with high intracellular dye concentration.

Dineley KE, Malaiyandi LM, Reynolds IJ.

Mol Pharmacol. 2002 Sep;62(3):618-27.

PMID:
12181438
48.

Nitric oxide decreases the sensitivity of pulmonary endothelial cells to LPS-induced apoptosis in a zinc-dependent fashion.

Tang ZL, Wasserloos KJ, Liu X, Stitt MS, Reynolds IJ, Pitt BR, St Croix CM.

Mol Cell Biochem. 2002 May-Jun;234-235(1-2):211-7.

PMID:
12162436
49.
50.

Nitric oxide-induced changes in intracellular zinc homeostasis are mediated by metallothionein/thionein.

St Croix CM, Wasserloos KJ, Dineley KE, Reynolds IJ, Levitan ES, Pitt BR.

Am J Physiol Lung Cell Mol Physiol. 2002 Feb;282(2):L185-92.

Supplemental Content

Loading ...
Support Center